Compare QUIK & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUIK | NTHI |
|---|---|---|
| Founded | 1988 | 2008 |
| Country | United States | United States |
| Employees | 51 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.8M | 178.4M |
| IPO Year | 1997 | N/A |
| Metric | QUIK | NTHI |
|---|---|---|
| Price | $16.51 | $4.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $11.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 376.6K | 61.3K |
| Earning Date | 05-12-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,112,000.00 | N/A |
| Revenue This Year | $75.17 | N/A |
| Revenue Next Year | $16.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.80 | $3.20 |
| 52 Week High | $16.89 | $12.99 |
| Indicator | QUIK | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 73.88 | 23.10 |
| Support Level | $5.67 | $4.00 |
| Resistance Level | N/A | $5.82 |
| Average True Range (ATR) | 1.24 | 0.49 |
| MACD | 0.35 | 0.03 |
| Stochastic Oscillator | 90.67 | 9.78 |
QuickLogic Corp is a fabless semiconductor company developing programmable logic semiconductor technologies, including embedded Field Programmable Gate Array (eFPGA) intellectual property (IP) and specialized FPGA devices. Its product offerings include the eFPGA IP licensing business and associated professional services, as well as a range of FPGA silicon products, including EOS, ArcticLink III, PolarPro 3, PolarPro II, PolarPro, and Eclipse II products, among others. The company's customers come from various markets, including aerospace and defense, industrial and infrastructure systems, data processing and computing platforms, and certain embedded and edge computing applications. Geographically, it generates maximum revenue from North America and the rest from Asia Pacific and Europe.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).